Creating precisely tuned medicines so patients can breathe freely

We are pioneering a new therapeutic approach to treat debilitating ear, nose and throat (ENT) diseases that impact the lives of millions of people.

Technology Platform for ENT

Lyra’s transmucosal therapeutic system, now being evaluated in a clinical study, is designed to directly target tissues that are difficult or impossible to access with existing therapies.

Learn More

First Product Focused on CRS

Our first product candidate is designed to address chronic rhinosinusitis (CRS), which affects about 27 million – 11% of adults – in the U.S., and has no approved pharmaceutical treatments.

Learn More

Our Vision at Lyra

We are working to transform the ENT treatment paradigm by providing effective front-line solutions for physicians and new treatment options for their patients.

Learn More

Featured News

September 17, 2018

Lyra Therapeutics to Present Clinical Data from Phase 1 Study of LYR-210 for the Treatment of Chronic Rhinosinusitis

More News